Medway school of pharmacy

Paraskevi obtained her degree in Pharmacy (BSc) from School of Pharmacy, University of Patras, Greece in 1993. She completed her MSc in Industrial Pharmaceutics in 1998 and her PhD on Pharmaceutical Technology (“Asialofetuin-bearing Liposomes for Targeting to Hepatocytes”) in 2000 at the University of Patras, Greece. She worked as a Research Fellow at the School of Pharmacy, University of Nottingham on a BBSRC funded project researching nanoparticle assembly from novel polymers and their potential application for brain tumors. She took up her post as a Lecturer in Medway School of Pharmacy in November 2006.

back to top

Her research interests focus on drug delivery systems, specifically liposomes and nanoparticles and their potential therapeutic application to biological systems. Surface modification of those systems using various molecules such as ligands or antibodies is a main interest, as site specific drug accumulation (active targeting) can be achieved. Current studies include the development of arsonoliposomes for brain tumor therapy by targeting cancer and neural cancer stem cells. Also, she is interested and is developing particles loaded with MRI contrast agents for either therapeutic or diagnostic purposes.

back to top

• Puri S, Kallinteri P, Higgins S, Hutcheon GA, Garnett MC.(2008) Drug incorporation and release of water soluble drugs from novel functionalized poly(glycerol adipate) nanoparticles. J Control Release 125(1):59-67.
• Meng W, Kallinteri P, Walker DA, Parker TL, Garnett MC (2007). Evaluation of poly (glycerol-adipate) nanoparticle uptake in an in vitro 3-d brain tumor co-culture model. Exp Biol Med (Maywood) 232(8):1100-8.
• Kallinteri P,Garnett MC (2007). Polymeric nanoparticles for drug delivery. In: KUMA, C., ed. Nanotechnologies for the life sciences. 1st. 10 Nanomaterials for medical diagnosis and therapy. Wiley VCH, pp. 409-470
• Meng W, Parker TL, Kallinteri P, Walker DA, Higgins S, Hutcheon GA, Garnett MC (2006). Uptake and metabolism of novel biodegradable poly (glycerol-adipate) nanoparticles in DAOY monolayer. J Control Release 116(3):314-21. Epub 2006 Oct 3.
• Garnett MC, Kallinteri P (2006). Nanomedicines and nanotoxicology: some physiological principles. Occup Med (Lond). 56(5):307-11. Review.
• Kallinteri P, Higgins S, Hutcheon GA, St Pourcain CB, Garnett MC (2005). Novel functionalized biodegradable polymers for nanoparticle drug delivery systems. Biomacromolecules. 6(4):1885-94.
• Kallinteri P, Fatouros D, Klepetsanis P, Antimisiaris SG (2004). Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability. J Liposome Res. 14(1-2):27-38.
• Kallinteri P, Antimisiaris SG, Karnabatidis D, Kalogeropoulou C, Tsota I, Siablis D (2002). Dexamethasone incorporating liposomes: an in vitro study of their applicability as a slow releasing delivery system of dexamethasone from covered metallic stents. Biomaterials 23(24):4819-26.
• Kokkona M, Kallinteri P, Fatouros D, Antimisiaris SG (2002). Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition. Eur J Pharm Sci. 9(3):245-52.
• Kallinteri P, Liao WY, Antimisiaris SG, Hwang KH (2001). Characterization, stability and in-vivo distribution of asialofetuin glycopeptide incorporating DSPC/CHOL liposomes prepared by mild cholate incubation. J Drug Targeting 9(2):155-68.
• Kallinteri P, Papadimitriou E, Antimisiaris SG (2001).Uptake of liposomes which incorporate a glycopeptide fraction of asialofetuin by HepG2 cells. J. Liposome Res. 11(2-3):175 – 193.

back to top